Nonclassical congenital adrenal hyperplasia (NCAH) can lead to the production of excess male hormones. It is usually a mild condition and often doesn’t need to be treated. Nonclassical ...

Congenital adrenal hyperplasia (CAH) is a group of genetic conditions that hinders normal hormone levels in your adrenal ...

BOSTON — Crinecerfont, an investigational oral selective corticotropin-releasing factor type 1 receptor antagonist, benefits both adults and children with congenital adrenal hyperplasia (CAH ...

Congenital adrenal hyperplasia is a condition that causes the adrenal glands to produce too much androgen, the male sex hormone. This may result in early puberty and other symptoms.

SAN DIEGO — Neurocrine Biosciences announced on Tuesday that an experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial, bringing the company a step closer to ...

Learn about a new drug for classic congenital adrenal hyperplasia (CAH). A top expert explains crinecerfont and its benefits, how it works, and its impact on CAH treatment.

References: Neurocrine Biosciences announces FDA approval of Crenessity™ (crinecerfont), a first-in-class treatment for children and adults with classic congenital adrenal hyperplasia.

Study shows crinecerfont aids patients with congenital adrenal hyperplasia. Crinecerfont results in a greater decrease from baseline in the mean daily glucocorticoid dose among patients with ...

CRF1 receptor antagonists in congenital adrenal hyperplasia: A systematic review and meta-analysis of phase 2 open-label and phase 3 clinical trials, Endocrine and Metabolic Science, 18, (100247 ...

After seven decades with no advances in the treatment of the genetic disorder classic congenital adrenal hyperplasia (CAH), Neurocrine Biosciences has scored FDA approval for its first-in-class ...